Cook Meredith sold $41K of ANIP
Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) sold 500 shares of ANI PHARMACEUTICALS INC (ANIP) at $81.84 on 2026-07-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the specific open-market sale of 500 shares at $81.84 on 2026-07-13, with holdings after the trade of 77,390 shares.
Market read
Traders may briefly monitor insider activity, but a 10b5-1 sale of ~$40.9K is generally not a fundamental catalyst.
What to watch
The transaction size is small relative to typical institutional flows, and 10b5-1 plans are designed to reduce timing-based inference.
Background
This is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals, reported by an officer (SR. VP, General Counsel & SEC).
Ticker impact
Meredith Cook, ANI Pharmaceuticals’ General Counsel, sold 500 shares on 2026-07-13 at $81.84 under a 10b5-1 plan.
Low likelihood of a sustained price move; any impact would be limited to intraday sentiment around the filing.
The filing is a Form 4 open-market sale, explicitly under a pre-arranged 10b5-1 plan, and the disclosed transaction value is about $40.9K.
Market effects
No clear read-across to the biotech/pharma sector from a single planned insider sale.
None indicated.
None indicated.
Counterpoint
Even planned 10b5-1 sales can coincide with internal views on liquidity or risk, so some traders may still treat it as a mild negative sentiment signal.
Key entities
- issuerANI Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderMeredith Cook
Officer (SR. VP, General Counsel & SEC) who executed the sale under a 10b5-1 plan.
